Míriam Mañosa

Míriam Mañosa

Auto-generated profile, based on publicly available information

Míriam Mañosa

Gastroenterology Department, Hospital Germans Trias i Pujol, Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas, Badalona, Spain

Research Focus & Metrics

Academic Career Length

16Years (2011-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
3 October 2018 in Alimentary Pharmacology & Therapeutics
Verified
Journal Article
Open access
PDF file
MCMaría Chaparro
María Chaparro
AGAna Garre
Ana Garre
ERElena Ricart
Elena Ricart
MIMarisa Iborra
Marisa Iborra
FMFrancisco Mesonero
Francisco Mesonero
GGGETECCU study group
GETECCU study group
Summary: Background: Effectiveness of vedolizumab in real world clinical practice is unknown.Aim: To evaluate the short and long‐term effectiveness of vedolizumab in patients with inflammatory bowel disease (IBD).Methods: Patients who received at least 1 induction dose of vedolizumab were included. Effectiveness was defined based on Harvey‐Bradshaw index (HBI) in Crohn's disease (CD) and Partial Mayo Score (PMS) in ulcerative colitis (UC). Short‐term response was assessed at week 14. Variables associated with short‐term remission were identified by logistic regression analysis. The Kaplan‐Meier method was used to evaluate the long‐term durability of vedolizumab treatment. Cox model was used to identify factors associated with discontinuation of treatment and loss of response.Results: 521 patients were included (median follow‐up 10 months [interquartile range 5‐18 months]). At week 14, 46.8% had remission and 15.7% clinical response. CD (vs UC), previous surgery, higher CRP concentration and disease severity at baseline were significantly associated with impaired response. The rate of vedolizumab discontinuation was 37% per patient‐year of follow‐up (27.6% in UC and 45.3% in CD, P < 0.01). CD (vs UC), anaemia at baseline, steroids during induction and CRP concentration were associated with lower durability of treatment. Seven per cent of patients developed adverse events, infections being the most frequent.Conclusions: Over 60% of IBD patients respond to vedolizumab. Many patients discontinue treatment over time. CD and disease burden impair both short‐ and long‐term response. Vedolizumab seems to be safe in clinical practice.

19 December 2012 in Scandinavian Journal of Gastroenterology
Verified
Journal Article
Closed access
MMMíriam Mañosa
Míriam Mañosa
MNMercè Navarro-Llavat
Mercè Navarro-Llavat
LMLaura Marín
Laura Marín
YZYamile Zabana
Yamile Zabana
ECEduard Cabré
Eduard Cabré
EDEugeni Domènech
Eugeni Domènech
Aim. The aim was to assess the impact of inflammatory bowel disease (IBD) and its treatment on fertility, pregnancy outcomes, and breastfeeding. IBD is a chronic inflammatory condition that is usually diagnosed in young adulthood. Patients are often concerned about fertility and pregnancy outcomes. Methods. A structured questionnaire was posted to 850 adults with IBD followed-up on in a single center. Results. A total of 503 patients (59%) with a median age of 40 years and equally distributed for gender and type of IBD returned the questionnaire. Overall, 71% of the patients had a total of 659 children, 36% of whom were born after the diagnosis. A total of 132 miscarriages were registered, 46% after the diagnosis of IBD. Most childless patients stated that having no children was a personal decision, and only 6% of them were evaluated and diagnosed with infertility. Pregnancies after diagnosis of IBD had a higher probability of caesarean section and preterm delivery. IBD-related drug therapy was discontinued in 16% of the pregnancies, mainly as a result of medical advice. Babies born after the diagnosis of IBD were less often breastfed. Conclusions. The infertility rate among IBD patients seems to be similar to that seen in the general population. However, a large proportion of patients chose to remain childless. Vaginal delivery and breastfeeding are less likely to occur in babies born after the diagnosis. Suitable information for patients to avoid unwarranted concerns about adverse reproductive outcomes, as well as improved obstetrical and perinatal management, still seems to be necessary.

25 January 2018 in Alimentary Pharmacology & Therapeutics
Verified
Journal Article
Closed access
PDF file
MMM. Mañosa
M. Mañosa
MCM. Calafat
M. Calafat
RFR. de Francisco
R. de Francisco
CGC. García
C. García
MCM. J. Casanova
M. J. Casanova
GEGeteccu
Geteccu

19 August 2019 in Alimentary Pharmacology & Therapeutics
Verified
Journal Article
Open access
PDF file
MCMargalida Calafat
Margalida Calafat
MMMíriam Mañosa
Míriam Mañosa
FCFiorella Cañete
Fiorella Cañete
ERElena Ricart
Elena Ricart
EIEva Iglesias
Eva Iglesias
TGThe Eneida Registry Of Geteccu
The Eneida Registry Of Geteccu
Summary: Background: Thiopurines are the most widely used immunosuppressants in IBD although drug‐related adverse events (AE) occur in 20%‐30% of cases.Aim: To evaluate the safety of thiopurines in elderly IBD patientsMethods: Cohort study including all adult patients in the ENEIDA registry who received thiopurines. Patients were grouped in terms of age at the beginning of thiopurine treatment, specifically in those who started thiopurines over 60 years or between 18 and 50 years of age. Thiopurine‐related AEs registered in the ENEIDA database were compared.Results: Out of 48 752 patients, 1888 started thiopurines when over 60 years of age and 15 477 under 50 years of age. Median treatment duration was significantly shorter for those who started thiopurines >60 years (13 [IQR 2‐55] vs 32 [IQR 5‐82] months; P < .001). Patients starting >60 years had higher rates of all types of myelotoxicity, digestive intolerance and hepatotoxicity. Thiopurines were discontinued due to AEs (excluding malignancies and infections) in more patients starting >60 years (67.2% vs 63.1%; P < .001). Elderly age and female sex were independent risk factors for most AEs.Conclusion: In elderly IBD patients, thiopurines are associated with an increased risk of non‐infectious, non‐neoplastic, AEs.

7 August 2022 in Digestive and Liver Disease
Verified
Journal Article
Closed access
MMMíriam Mañosa
Míriam Mañosa
AFAgnès Fernández-Clotet
Agnès Fernández-Clotet
PNPilar Nos
Pilar Nos
MMMARIA DOLORES MARTIN-ARRANZ
MARIA DOLORES MARTIN-ARRANZ
NMNoemí Manceñido
Noemí Manceñido
EDEugeni Domènech
Eugeni Domènech

1 October 2011 in Journal of Crohn's and Colitis
Verified
Journal Article
Closed access
MMMíriam Mañosa
Míriam Mañosa
VGValle García
Valle García
LCLuisa Castro
Luisa Castro
OGOrlando García-Bosch
Orlando García-Bosch
MCMaría Chaparro
María Chaparro
MAMariam Aguas
Mariam Aguas
Few data are available on the efficacy of methotrexate (MTX) in ulcerative colitis (UC). To evaluate the efficacy and safety of MTX in UC patients. UC patients who had been treated with MTX were identified from the databases of 8 Spanish IBD referral hospitals. Patients were included in the study if they received MTX for steroid dependency or steroid refractoriness. Therapeutic success was defined as the absence of UC-related symptoms, complete steroid withdrawal and no requirement of rescue therapies within the first 6 months after starting MTX. Forty patients were included, 70% treated for steroid dependency and 27% for steroid refractoriness. Thiopurines had been previously attempted in 87.5% of patients. The median dose of MTX used for induction was 25mg (IIQ 17.5-25) weekly given parenterally in 82.5% of cases. Eighty-five percent of patients were on steroids when MTX was started. Forty-five percent of patients met criteria for therapeutic success. Initial treatment failures were mainly due to inefficacy (50%) or intolerance (36%). After a median follow-up of 28 months (IQR 22-47), 38% of patients with initial therapeutic success required new steroid courses, 22% started biological therapy, and only 1 patient required colectomy. The cumulative probability of maintaining steroid-free clinical remission was 60%, 48%, and 35% at 6, 12, and 24 months after starting MTX, respectively. Eleven patients (27.5%) experienced adverse events, leading to MTX discontinuation in only 8 of them. MTX appears to be effective to maintain clinical remission in UC, at least in the short-term, with an acceptable safety profile.